Procalcitonin is a promising biomarker for antibiotic therapy because its levels rise and fall quickly with bacterial infections. A multi-database literature search was reviewed with 3 primary prospective randomized control trials used in further analysis. The results indicated that a procalcitonin-guided antibiotic protocol reduces the number of days a patient has to take antibiotics while having no effect on mortality when compared with control groups. Short-term studies did not show a difference in the intensive care unit length of stay, infection relapse rate, super-infection rate, or multidrug-resistant bacteria rate between the procalcitonin-protocol and control group. Because procalcitonin-guided antibiotic therapy has been shown to reduce the duration of treatment with antibiotics in critically ill patients without worsening the mortality rate or other outcomes, the implementation of a procalcitonin-guided antibiotic therapy should be considered for patients with proven or highly suspected bacterial infections in the intensive care unit.
Skip Nav Destination
Article navigation
1 April 2015
Feautures|
April 01 2015
Procalcitonin-Guided Antibiotic Therapy Duration in Critically Ill Adults
Caroline Walker, RN, MSN, BSN, AGACNP-BC
Caroline Walker, RN, MSN, BSN, AGACNP-BC
Caroline Walker is Adult Gerontology Acute Care Nurse Practitioner, University of Pennsylvania School of Nursing, 418 Curie Boulevard, Philadelphia, PA 19104 ([email protected]).
Search for other works by this author on:
AACN Adv Crit Care (2015) 26 (2): 99–106.
Citation
Caroline Walker; Procalcitonin-Guided Antibiotic Therapy Duration in Critically Ill Adults. AACN Adv Crit Care 1 April 2015; 26 (2): 99–106. doi: https://doi.org/10.4037/NCI.0000000000000079
Download citation file:
Sign in
Don't already have an account? Register
Short-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access